All In Biotech

Drug Trial Radar · NCT06755944

A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase Ⅱb/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

360

Actual

Start

Dec 15, 2024

Primary completion

Jun 9, 2025

Study completion Nov 25, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase Ⅱb/Ⅲ clinical study to evaluate the efficacy and safety of XY03-EA tablets, a novel oral neuroprotective agent, and explore the dose-response relationship in patients with acute ischemic stroke. In the Phase Ⅱb stage, 360 eligible subjects were enrolled and randomly assigned to four XY03-EA dose groups and one placebo group in a 1:1:1:1:1 ratio. The primary endpoint was the proportion of patients with a modified Rankin Scale (mRS) score ≤ 1 at Day 90 after the start of study treatment.

Conditions

  • Stroke, Ischemic

Interventions

  • XY03-EA 150 mg (per dose)Drug

    XY03-EA tablets, 150 mg/tablet, 1 tablet orally, three times daily (Tid), for 90 days

  • XY03-EA 300 mg (Regimen A)Drug

    XY03-EA tablets, 150 mg/tablet, 2 tablets orally, Tid, for 90 consecutive days

  • XY03-EA 300 mg (Regimen B)Drug

    XY03-EA tablets, 150 mg/tablet, 2 tablets orally, Tid, from Day 1 to Day 14

  • XY03-EA 450 mg (per dose)Drug

    XY03-EA tablets, 150 mg/tablet, 3 tablets orally, Tid, for 90 days

  • Matching PlaceboDrug

    Matching placebo tablets, orally, Tid, for 90 days (or as specified per arm)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with Modified Rankin Scale (mRS) score ≤ 1 point at 90 days after administration.Time frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shijiazhuang Yiling Pharmaceutical Co., Ltd

    Shijiazhuang, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.